National Academies Press: OpenBook

Heritable Human Genome Editing (2020)

Chapter: Appendix D: Acronyms and Abbreviations

« Previous: Appendix C: Glossary
Suggested Citation:"Appendix D: Acronyms and Abbreviations." National Academy of Medicine, National Academy of Sciences, and the Royal Society. 2020. Heritable Human Genome Editing. Washington, DC: The National Academies Press. doi: 10.17226/25665.
×
Page 209
Suggested Citation:"Appendix D: Acronyms and Abbreviations." National Academy of Medicine, National Academy of Sciences, and the Royal Society. 2020. Heritable Human Genome Editing. Washington, DC: The National Academies Press. doi: 10.17226/25665.
×
Page 210

Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.

Appendix D Acronyms and Abbreviations AG-haESCs Androgenetic haploid embryonic stem cells AIDS Acquired immune deficiency syndrome APHIS Animal and Plant Health Inspection Service ART Assisted reproductive technologies CAR-T cells Chimeric antigen receptor T cells Cas CRISPR associated protein Cas9 CRISPR associated protein 9 CF Cystic Fibrosis CRISPR Clustered regularly-interspaced short palindromic repeats DNA Deoxyribonucleic acid ES cell Embryonic stem cell ESHRE European Society of Human Reproduction and Embryology FDA Food and Drugs Administration FH Familial Hypercholesterolemia GCP Good clinical practice gRNA Guide ribonucleic acid GWAS Genome wide association study HDR Homology directed repair HFEA Human Fertility and Embryology Authority HHGE Heritable human genome editing HIV Human immunodeficiency syndrome hPGCLC Human primordial germ-like cells ICM Inner cell mass ICSI Intracytoplasmic sperm injection IFFS International Federation of Fertility Societies iPS cell Induced pluripotent stem cell ISAP International Scientific Advisory Panel IVF In vitro fertilization IVG In vitro gametogenesis LDL Low-density lipoprotein MII Metaphase II MRT Mitochondrial replacement techniques MST Maternal spindle transfer mtDNA Mitochondrial DNA NGS Next generation sequencing NHEJ Non-homologous end joining ntES cell Nuclear transfer embryonic stem cell OHSS Ovarian hyperstimulation syndrome PAM Protospacer adjacent motif PB Polar body PCR Polymerase chain reaction PGC Primordial germ cells PGCLC Primordial germ-like cells PREPUBLICATION COPY | UNCORRECTED PROOFS 209

PGT Preimplantation genetic testing PNT Pronuclear transfer RNA Ribonucleic acid SCD Sickle cell disease SNP Single nucleotide polymorphism SNV Single nucleotide variants SSC Spermatagonial stem cells TALEN Transcription activator-like effector nuclease WGS Whole-genome sequencing WHO World Health Organization ZFN Zinc finger nuclease PREPUBLICATION COPY | UNCORRECTED PROOFS 210

Next: Acknowledgment of Reviewers »
Heritable Human Genome Editing Get This Book
×
Buy Prepub | $69.00 Buy Paperback | $60.00
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Heritable human genome editing - making changes to the genetic material of eggs, sperm, or any cells that lead to their development, including the cells of early embryos, and establishing a pregnancy - raises not only scientific and medical considerations but also a host of ethical, moral, and societal issues. Human embryos whose genomes have been edited should not be used to create a pregnancy until it is established that precise genomic changes can be made reliably and without introducing undesired changes - criteria that have not yet been met, says Heritable Human Genome Editing.

From an international commission of the U.S. National Academy of Medicine, U.S. National Academy of Sciences, and the U.K.'s Royal Society, the report considers potential benefits, harms, and uncertainties associated with genome editing technologies and defines a translational pathway from rigorous preclinical research to initial clinical uses, should a country decide to permit such uses. The report specifies stringent preclinical and clinical requirements for establishing safety and efficacy, and for undertaking long-term monitoring of outcomes. Extensive national and international dialogue is needed before any country decides whether to permit clinical use of this technology, according to the report, which identifies essential elements of national and international scientific governance and oversight.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  6. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  7. ×

    View our suggested citation for this chapter.

    « Back Next »
  8. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!